Find in Library

Lapatinib is a small molecule that reversibly inhibits the tyrosine kinase activity of EGFR and HER2. It is indicated in the treatment of breast carcinoma overexpressing HER2 (ErB2), in combination with capecitabine, in patients with advanced or metastatic disease, progressing after treatment with anthracyclines, taxanes and trastuzumab. We report the case of a 53-year-old patient with hepatic and local disease at diagnosis, treated as first line with trastuzumab, pertuzumab and docetaxel. After 9 months, encephalic progression was documented. The patient was treated with radiotherapy, trastuzumab and pertuzumab. After recurrence of the encephalic disease, the patient started therapy with lapatinib and capecitabine, leading to stable disease at local, hepatic and cerebral level, with an excellent tolerability profile (Oncology).